0.57
+0.1215(+27.12%)
Currency In USD
| Previous Close | 0.45 |
| Open | 0.55 |
| Day High | 0.73 |
| Day Low | 0.49 |
| 52-Week High | 4.06 |
| 52-Week Low | 0.2 |
| Volume | 115.86M |
| Average Volume | 1.92M |
| Market Cap | 25.6M |
| PE | -0.17 |
| EPS | -3.42 |
| Moving Average 50 Days | 0.54 |
| Moving Average 200 Days | 0.77 |
| Change | 0.12 |
If you invested $1000 in NKGen Biotech, Inc. Common Stock (NKGN) since IPO date, it would be worth $99.74 as of February 22, 2025 at a share price of $0.57. Whereas If you bought $1000 worth of NKGen Biotech, Inc. Common Stock (NKGN) shares 1 year ago, it would be worth $569.5 as of February 22, 2025 at a share price of $0.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options.SANTA ANA, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”)
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site
GlobeNewswire Inc.
Feb 19, 2025 1:00 PM GMT
SANTA ANA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natu
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease
GlobeNewswire Inc.
Feb 13, 2025 1:00 PM GMT
The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse events following troculeucel therapy. Troculeucel therapy was well-tolerated and resulted in beneficial